Legalcategory U.S. Supreme Court rebuffs Novartis, allows generic versions of MS drug October 14, 2022 Legalcategory U.S. Supreme Court asked to allow generics of Novartis MS drug Gilenya October ...

The affected companies are Novartis Pharmaceuticals Corporation, Bayer Corporation, AbbVie, Regeneron Pharmaceuticals, ...

Novartis is one of the world's top ... Shared services and Corporate. The company's Pharmaceuticals Division focuses on researching, developing and manufacturing treatments across a variety ...

Novartis is a pharmaceutical powerhouse with a global ... from research to execution. Novartis' corporate culture has also undergone significant transformation over the years.

Novartis is making two investments in new radiopharmaceutical manufacturing sites in the US. The Swiss pharmaceutical giant will open a third US radioligand plant in Carlsbad, California, to serve the ...

Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...

Judge Andrews of the District of Delaware recently denied Novartis’s request for a preliminary injunction against MSN Pharmaceuticals. Novartis Pharm. Corp. v. MSN Pharm. Inc., Civil Action No ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

Novartis AG is a holding company ... form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central ...

Two new papers by a team of researchers at Boston University, the Indiana University School of Medicine and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the German Center for ...

This is where Novartis is striving to re-imagine and innovate the pharma industry to improve and extend people's lives. The American-Swiss multinational pharmaceutical corporation is based in Basel, ...

The 340B Drug Pricing Program continues to provide critical support for covered entities, although the program is subject to ongoing scrutiny ...